Steatohepatitis is an advanced stage of liver disease. While alcohol can be the main cause, it isn't always. Let's look at treatment options and more: ...

Non-alcoholic steatohepatitis often occurs in individuals with metabolic risk factors like obesity, type 2 diabetes, hypothyroidism, deranged lipid profile or raised blood pressure.

Steatohepatitis can arise from alcohol consumption or during the course of certain health conditions, such as hypertension and type 2 diabetes. Treatment for steatohepatitis typically involves ...

North America is anticipated to provide a significant share of non-alcoholic steatohepatitis therapeWilmington, Delaware, United States, July 07, 2023 (GLOBE NEWSWIRE) -- The global non-alcoholic ...

The global non-alcoholic steatohepatitis treatment market size was USD 7.70 billion in 2024, estimated at USD 9.85 billion in 2025, and is expected to reach around USD 90.97 billion by 2034 ...

Non-alcoholic steatohepatitis (NASH) is a condition that falls under the umbrella of non-alcoholic fatty liver diseases. About 12 percent of the population in the United States is affected by NASH, ...

Metabolic dysfunction–associated steatohepatitis (MASH) is the new term for non-alcoholic steatohepatitis (NASH). There are several reasons for the name change.

The term ‘non-alcoholic steatohepatitis’ was first proposed by Ludwig et al. 1 in 1980 to denote steatohepatitis in absence of alcohol abuse. Well-established risk factors for non-alcoholic ...

It was a term coined in the 1980s, after Jurgen Ludwig and colleagues used “non-alcoholic steatohepatitis” to describe a liver beaded with extra fat, but whose disease happened in the absence ...